US Stock Market Movement | Cardiovascular Pharmaceutical Company Braveheart Bio (BRVE.US) Debuts on the US Stock Market, Shares Surge Over 75% After Opening
As of press time, the stock has risen more than 75%, trading at $31.405.
According to Zhihui Finance APP, on Thursday, cardiovascular drug company Braveheart Bio (BRVE.US) debuted on the US stock market. As of press time, the stock was up over 75%, trading at $31.405. The IPO price was $18. Founded in 2024, Braveheart Bio is a late-stage biopharmaceutical company focused on developing innovative therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company’s core drug candidate, BHB-1893 (also known as HRS-1893), is an oral small molecule cardiac myosin inhibitor that specifically inhibits cardiac myosin ATPase activity, normalizing myocardial contractility, reducing left ventricular hypertrophy, and improving diastolic compliance. In September 2025, the drug obtained exclusive global (excluding Greater China) licensing rights from Jiangsu Hengrui Pharmaceuticals in China.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave prices upsized USD 3.7 billion convertible senior notes offering
BioStem secures USD 40 million equity facility via private placement with Roth affiliate
Adient names Peter Carlin CFO effective Nov. 16, 2026
Barclays: The Bank of England's slower pace of balance sheet reduction is expected to ease pressure on the repo market and UK government bonds
Barclays strategists stated that the Bank of England's plan to slow down the pace of bond sales will ease pressures on repo operations and also offer support to the stressed ultra-long-term UK government bonds.
Crypto prices
More
